|
En-Zhi
Jia, Zhi-Jian Yang, Zhen-Zhen Wang, Wei-Chong Qian, Xin-Li Li,
Hai-Yan Wang, Wen-Zhu Ma, Department of Cardiovascular Medicine,
the First Affiliated Hospital of Nanjing Medical University, Nanjing
210029, Jiangsu Province, China
Shi-Wei Chen, Guang-Yao Qi, Chun-Fa You, The Disease Control
Center of Pizhou City, Pizhou 221300, Jiangsu Province, China
Jian-Feng Ma, Department of Central Clinical Laboratory, the
First Affiliated Hospital of Nanjing Medical University, Nanjing
210029, Jiangsu Province, China
Jing-Xin Zhang, Department of Nuclear Medicine, the First
Affiliated Hospital of Nanjing Medical University, Nanjing 210029,
Jiangsu Province, China
Correspondence to: Dr. En-Zhi Jia, Department of
Cardiovascular Epidemiology, the First Affiliated Hospital of
Nanjing Medical University, Guangzhou road 300, Nanjing 210029,
Jiangsu Province, China. enzhijia@yahoo.com.cn
Telephone: +86-13951623205
Received: 2003-11-17
Accepted: 2004-02-01
Abstract
AIM: To investigate the association between true insulin and
proinsulin and clustering of cardiovascular risk factors.
METHODS: Based on the random stratified sampling principles, 1196
Chinese people (533 males and 663 females, aged 35-59 years with an
average age of 46.69 years) were recruited. Biotin-avidin based
double monoclonal antibody ELISA method was used to detect the true
insulin and proinsulin, and a risk factor score was set to evaluate
individuals according to the number of risk factors.
RESULTS: The median (quartile range) of true insulin and proinsulin
was 4.91 mIu/L (3.01-7.09 mIu/L) and 3.49 pmol/L (2.14-5.68 pmol/L)
respectively, and the true insulin level of female subjects was
significantly higher than that of male subjects (P = 0.000),
but the level of proinsulin displayed no significant difference
between males and females (P = 0.566). The results of
covariate ANOVA after age and sex were controlled showed that
subjects with any of the risk factors had a significantly higher
true insulin level (P = 0.002 for hypercholesterolemia, P
= 0.021 for high low-density lipoprotein cholesterol, P =
0.003 for low high-density lipoprotein cholesterol, and P =
0.000 for other risk factors) and proinsulin level (P = 0.001
for low high-density lipoprotein cholesterol, and P = 0.000
for other risk factors) than those with no risk factors.
Furthermore, subjects with higher risk factor scores had a higher
true insulin and proinsulin level than those with lower risk factor
scores (P = 0.000). The multiple linear regression models
showed that true insulin and proinsulin were significantly related
to cardiovascular risk factor scores respectively (P =
0.000).
CONCLUSION: True insulin and proinsulin are significantly associated
with the clustering of cardiovascular risk factors.
ã 2005
The WJG Press and Elsevier Inc. All rights reserved.
Key words: True insulin;
Proinsulin; Cardiovascular diseases
Jia EZ, Yang ZJ, Chen
SW, Qi GY, You CF, Ma JF, Zhang JX, Wang ZZ, Qian WC, Li XL, Wang HY,
Ma WZ. Significant association of insulin and proinsulin with
clustering of cardiovascular risk factors. World J Gastroenterol 2004; 11(1): 149-153
http://www.wjgnet.com/1007-9327/10/149.asp
INTRODUCTION
Dyslipidemia, hypertension, hyperinsulinemia and obesity
(special central obesity) have been recognized as potent risk
factors for coronary heart disease in adults[1-3]. In
fact, the clustering of the above cardiovascular risk factors often
occurs in adults and has been termed syndrome X[4],
deadly quartet[5], insulin resistance syndrome[6],
and multiple metabolic syndrome[7]. Insulin resistance
emerges as a common pathogenetic denominator underlying the above
risk factor clustering[8]. In the earlier studies,
insulin concentration was measured using radioimmunoassays with
polyclonal antibodies[9], which cross-react with largely
inactive insulin precursor molecules such as proinsulin (PI) and
des-31, 32 proinsulin; hence it is called immunoreactive insulin (IRI).
These proinsulin molecules (PI) can be distinguished from more
biologically active true insulin (TI) molecules by using highly
sensitive and specific two-site immunoassays based on monoclonal
antibodies[10]. After these assays became available,
several groups have reported that PI is more closely associated with
coronary heart disease[11], stroke[12], and hypertension[13]
than TI. It is possible that hyperinsulinemia in subjects with
insulin resistance syndrome may reflect increased PI concentration
rather than increased levels of insulin itself. To explore the
relationship between TI versus PI and cardiovascular risk factor
clustering, a population-based epidemiological investigation was
conducted in Pizhou City located in the mid-east of China.
MATERIALS AND METHODS
Study design and population
The Pizhou district, a rural area of 2097 km2, is
situated in the north of Jiangsu Province of China, with a
population of 1.52 million. From April 2001 to May 2001, a large
cross-sectional, community-based epidemiological study was
conducted. The people surveyed were adults aged between 35 and 59
years. Signed informed consents were obtained from all participants
and the study was approved by the Nanjing Medical University Ethics
Review Committee. A two-stage cluster-sampling scheme based on
existing census divisions was used to randomly select (with
probability proportional to size) 4 areas, each with a population
from 300 to 350 subjects, and samples were stratified by sex and age
group (5 years) to ensure representation of each part of the
population. Among 1351 individuals investigated, the response rate
was 88.5%, and the random sample and random-sample responder
populations closely reflected the actual distribution of age group
and sex in Pizhou area. Compared with the figures available from the
most recent census, the samples were generally found to be
representative in terms of sex and age group profiles, geographical
locations, marital status, socio-economic groups and education
levels. Data on sex and age groups and geographical locations
collected from non-respondents were compared with those of the
samples surveyed and no significant difference was detected between
them.
Anthropometric measurements
Anthropometric
measurements were performed after participants removed their shoes
and upper garments and donned an examining gown. Each measurement
was performed twice and the average was used in the analysis. Height
(HT) was measured to the nearest 0.1 cm using a wall-mounted
stadiometer. Weight (WT) was measured to the nearest 0.1 kg using a
hospital balance beam scale. Body mass index (BMI) was calculated as
weight (kg) divided by the square of height (m2). The
waist circumference (WC) was measured to the nearest 0.5 cm at the
point of narrowing between the umbilicus and xiphoid process (as
viewed from behind) and the waist circumference was used as a
judgement of upper-body adioposity. Blood pressure was measured in
the right arm with the participant seated and the arm bared. Three
readings were recorded for each individual, and the average of the
second and third reading was defined as the subject’s
blood pressure.
Laboratory
measurements
Twelve
hour fasting blood samples were drawn in the morning and the sera
were stored at -70 °C immediately after
centrifugation until assayed. All laboratory measurements were
conducted at the Central Clinical Laboratory in the First Affiliated
Hospital of Nanjing Medical University. Fasting blood glucose (FBG),
fasting total cholesterol (TCH), fasting triglyceride (TG) and
fasting high-density lipoprotein cholesterol (HDL-c) were determined
by enzymatic procedures on an automated autoanalyzer (AU 2700,
Olympus, Japan). The laboratory tests were monitored for precision
and accuracy of glucose and lipid measurements by the agency’s
surveillance program. Measurements on agency-assigned quality
control samples showed no consistent bias over time within or
between surveys. Low-density lipoprotein cholesterol (LDL-c) was
assessed by the Friedwald method[14]. The TI level was
measured using a highly sensitive two-site sandwich ELISA[15].
The detection limit was 5.0 pmol/L. The specificity of the assay
excluded intact, split (32-33) and des (31,32) proinsulin. There was
some cross-reactivity with the less abundant split (65-66)
proinsulin (30%) and des (64,65) proinsulin (63%). The PI level was
measured in a similar manner using another sensitive two-site
sandwich ELISA[16]. The detection limit in human serum
was 0.25 pmol/L. There was no cross-reactivity with human insulin
and human C-peptide. Howerer, the four major proinsulin conversion
intermediates reacted in various proportions of 65% to 99%. The
between- and within-assay coefficients of variation were 6.8%, 7.8%
for TI respectively and 6.7%,
7.8% for PI respectively. All measurements were performed in
duplicate. The four monoclonal antibodies including OXI-005,
HUI-018, PEP-001 and HUI-001 were kind gifts from Novo Nordisk,
Bagsvaerd, Denmark.
Definition
of risk factors
To investigate the relationship between TI versus PI and
cardiovascular risk factor clustering, we set a risk factor score to
rank individuals according to the number of the risk factors at the
time of survey. The following 9 factors and cut-off points were used
to build up this risk factor scores. Hypertension was defined when
systolic blood pressure (SBP) was ≥R140 mmHg and/or diastolic
blood pressure (DBP) ≥R90 mmHg or antihypertensive drugs were
taken because of previous hypertension according to the 1999 WHO/ISH
criteria[17]. Hyperglycemia
was diagnosed based on the fasting serum glucose >6.1 mmol/L
according to the American Diabetes Association (ADA) criteria[18]
or when the patient had a history of diabetes mellitus.
Hypercholesterolemia was defined as fasting total cholesterol
≥ 5.20 mmol/L. High LDL-c was defined as LDL-c ≥ 3.38
mmol/L. Low HDL-c was recognized as HDL-c≤1.04 mmol/L.
Hypertriglyceridemia was defined as fasting triglyceride ≥
1.70 mmol/L[19]. High TG/low HDL was considered as the
risk score and the cut-off point was triglyceride ≥1.70 mmol/L
and HDL-c≤1.04 mmol/L. Overall overweight was considered as
BMI ≥ 25.0 kg/m2 according to the WHO guidelines[20].
Visceral obesity was defined as waist circumference ≥85 cm in
males and ≥80 cm in females[21]. The final risk
factor scores varied from 0 to 5. 0; 1 indicates the exposure to any
one risk factor; 2, 3, and 4 indicate exposure to any combination of
2, 3, and 4 risk factors respectively; 5 indicates exposure to any
combination of 5 or more than 5 risk factors simultaneously.
Statistical analysis
All
data analyses were performed using Statistical Package for Social
Science (SPSS for Windows, version 10.0, 1999, SPSS Inc, Chicago,
IL). Data of BMI, WC, age and blood pressure were normally
distributed parameters and presented as mean±SD, whereas skewed
data including fasting blood glucose, fasting lipid, fasting TI and
fasting PI were logarithmically transformed before analysis and
expressed as a median and quartile range. Intergroup comparisons
were normally made with Student’s
t test, and analysis of covariance (ANCOVA) controlling the age and
sex was used to determine the relationship between risk factors and
TI versus PI. Stepwise multiple linear regression was used, P values
of 0.05 and 0.10 were used as the criteria for entry and removal at
each step respectively. P<0.05 was considered
statistically significant.
RESULTS
Anthropometric and biochemical characteristics of study
population
The anthropometric and biochemical characteristics of the
Chinese population studied are displayed in Table 1. Comparison
between males and females was carried out by unpaired t test. Due to
skewness, FBG, CH, TG, HDL-c, LDL-c, TI and PI were logarithmically
transformed before analysis. No significant difference was found
between males and females regarding their age, FBG, lipid and PI.
The SBP, DBP and WC were significantly higher in males than in
females. However, BMI and TI were significantly higher in females
than in males.
ANCOVA analysis of TI versus PI and risk factors
The logarithmically transformed values of TI and PI were
dependent variables respectively, and either the presence or absence
of risk factors was factor variable. The covariate ANOVA (ANCOVA)
after adjustment for age and sex was conducted. The results (Tables
2, 3) showed that after the age and sex were controlled, the
subjects with any of the above risk factors had a significantly
higher TI and PI level than those with no risk factors. Furthermore,
the subjects with higher risk factor scores had a higher TI and PI
level than the subjects with lower risk factor scores.
Multiple linear regression analysis for risk factors
Tables 4 and 5 show the multiple stepwise linear regression
analyses of the relationship between the dependent variables of TI
and PI respectively and the independent variables of age, sex, BMI,
WC, SBP, DBP, FBG, lipid, and risk factor scores. When the risk
factor scores were entered in the regression model before other
variables, the results presented in Table 3 indicated that the risk
factor scores, fasting blood glucose, sex, BMI, triglyceride and age
were significantly associated with the true insulin concentration.
Table 4 demonstrates that fasting blood glucose, risk factor scores,
BMI, age, triglyceride, low-density lipoprotein cholesterol remained
in the regression model and were significantly associated with the
concentration of proinsulin.
Table
1
Anthropometric and biochemical characteristics of study
population (mean±SD)
| Variables |
Male |
Female |
Total |
T |
P |
| AGE |
46.78±7.93 |
46.62±7.79 |
46.69±7.85 |
0.360 |
0.719 |
| SBP |
126.26±19.92 |
122.23±20.54 |
124.03±20.36 |
3.413 |
0.001 |
| DBP |
81.09±12.47 |
77.23±10.79 |
78.95±11.73 |
5.737 |
0.000 |
| FBG |
4.48
(4.07-4.94) |
4.42
(4.08-4.84) |
4.58
(4.07-4.88) |
0.492 |
0.623 |
| CH |
4.06
(3.50-4.71) |
3.98
(3.45-4.59) |
4.02
(3.48-4.63) |
1.578 |
0.115 |
| TG |
0.83
(0.59-1.24) |
0.77
(0.57-1.12) |
0.79
(0.57-1.18) |
1.957 |
0.051 |
| HDL |
1.04
(0.86-1.28) |
1.07
(0.89-1.27) |
1.06
(0.88-1.28) |
-1.405 |
0.160 |
| LDL |
2.54
(2.09-3.02) |
2.44
(2.05-2.88) |
2.48
(2.06-2.95) |
0.990 |
0.322 |
| BMI |
23.60±2.84 |
24.16±3.19 |
23.91±3.05 |
-3.128 |
0.002 |
| WC |
79.43±8.76 |
76.34±8.57 |
77.72±8.78 |
6.130 |
0.000 |
| TI |
4.24
(2.57-6.53) |
5.45
(3.51-7.47) |
4.91
(3.01-7.09) |
-5.164 |
0.000 |
| PI |
3.39
(2.04-5.65) |
3.58
(2.22-5.69) |
3.49
(2.14-5.68) |
-0.574 |
0.566 |
Table
2
ANCOVA analysis of TI and risk factors (age and sex are
covariate)
| Risk
factors |
|
N
(M/F) |
Median
(QR) |
F |
P |
| Hypertension |
Y |
149/142 |
5.71
(3.78-7.86) |
34.063 |
0.000 |
|
N |
384/521 |
4.60
(2.78-6.75) |
|
|
| Hyperglycemia |
Y |
17/22 |
7.50
(4.86-9.82) |
12.116 |
0.000 |
|
N |
516/641 |
4.82
(2.97-7.02) |
|
|
| Obesity |
Y |
149/227 |
6.41
(4.39-8.46) |
89.080 |
0.000 |
|
N |
382/436 |
4.24
(2.59-6.31) |
|
|
| Visceral
obesity |
Y |
137/214 |
6.37
(4.54-8.31) |
83.062 |
0.000 |
|
N |
395/449 |
4.25
(2.58-6.42) |
|
|
| High
CH |
Y |
85/78 |
5.69
(3.66-8.19) |
9.638 |
0.002 |
|
N |
448/585 |
4.76
(2.96-6.97) |
|
|
| High
LDL |
Y |
72/79 |
5.55
(3.19-7.84) |
5.301 |
0.021 |
|
N |
460/579 |
4.79
(2.97-7.00) |
|
|
| High
TG |
Y |
66/74 |
6.94
(4.89-8.62) |
39.522 |
0.000 |
|
N |
467/589 |
4.64
(2.82-6.76) |
|
|
| Low
HDL |
Y |
258/297 |
5.31
(3.19-7.57) |
8.829 |
0.003 |
|
N |
275/366 |
4.63
(2.82-6.69) |
|
|
| Risk
factor score |
0 |
134/180 |
3.81
(2.54-5.84) |
21.136 |
0.000 |
|
1 |
170/220 |
4.59
(2.79-6.63) |
|
|
|
2 |
123/151 |
5.19
(3.19-7.16) |
|
|
|
3 |
56/65 |
6.15
(4.23-7.92) |
|
|
|
4 |
29/27 |
7.75
(5.53-9.45) |
|
|
|
≥5 |
18/15 |
7.81
(5.74-10.20) |
|
|
M/F,
male/female; Y or N, presence or absence of risk factors.
Table
3
ANCOVA analysis of PI and risk factors (age and sex are
covariate)
|
Risk factors |
|
N (M/F) |
Median
(QR)
|
F |
P |
| Hypertension
|
Y
|
149/142
|
4.24(2.49-6.66)
|
20.523
|
0.000
|
|
N
|
384/521
|
3.34(2.02-5.31)
|
|
|
| Hyperglycemia
|
Y
|
17/22
|
11.20(7.54-17.52)
|
78.858
|
0.000
|
|
N
|
516/641
|
3.43(2.04-5.36)
|
|
|
| Obesity
|
Y
|
149/227
|
4.70(2.93-7.46)
|
70.508
|
0.000
|
|
N
|
382/436
|
3.13(1.84-4.72)
|
|
|
| Visceral
obesity
|
Y
|
137/214
|
4.67(3.05-7.56)
|
69.619
|
0.000
|
|
N
|
395/449
|
3.13(1.83-4.86)
|
|
|
| High
CH
|
Y
|
85/78
|
4.72(2.89-7.01)
|
25.807
|
0.000
|
|
N
|
448/585
|
3.36(2.02-5.32)
|
|
|
| High
LDL
|
Y
|
72/79
|
4.35(2.62-6.65)
|
15.775
|
0.000
|
|
N
|
460/579
|
3.40(2.04-5.39)
|
|
|
| High
TG
|
Y
|
66/74
|
5.37(3.63-8.57)
|
54.298
|
0.000
|
|
N
|
467/589
|
3.31(1.99-5.30)
|
|
|
| Low
HDL
|
Y
|
258/297
|
3.76(2.38-5.96)
|
12.049
|
0.001
|
|
N
|
275/366
|
3.29(1.95-5.31)
|
|
|
| Risk
factor score
|
0
|
134/180
|
2.77(1.61-4.29)
|
27.290
|
0.000
|
|
1
|
170/220
|
3.15(2.02-5.03)
|
|
|
|
2
|
123/151
|
3.97(2.39-6.03)
|
|
|
|
3
|
56/65
|
4.56(3.04-7.19)
|
|
|
|
4
|
29/27
|
6.18(3.83-11.39)
|
|
|
|
≥5
|
18/15
|
6.89(4.45-12.30)
|
|
|
M/F,
male/female; Y or N, presence or absence of risk factors.
Table
4
Multiple stepwise linear regression analysis with TI as a
dependent variable
| Parameter
|
Unstandardized coefficients
|
Standardized coefficients (Beta)
|
T
|
P
|
| B
|
SE
|
| Constant
|
-1.677
|
1.520
|
—
|
-1.103
|
0.270
|
| Risk
factor score
|
0.410
|
0.102
|
0.156
|
4.036
|
0.000
|
| FBG
|
0.558
|
0.112
|
0.142
|
4.992
|
0.000
|
| Sex
|
0.836
|
0.248
|
0.094
|
3.375
|
0.001
|
| BMI
|
0.162
|
0.052
|
0.111
|
3.121
|
0.002
|
| TG
|
0.196
|
0.093
|
0.063
|
2.108
|
0.035
|
| AGE
|
-3.18E-02
|
0.016
|
-0.056
|
-2.003
|
0.045
|
Table
5
Multiple stepwise linear regression analysis with PI as a
dependent variable
| Parameter
|
Unstandardized coefficients
|
Standardized coefficients
(Beta)
|
T
|
P
|
| B
|
SE
|
| Constant
|
-3.915
|
1.281
|
—
|
-3.058
|
0.002
|
| FBG
|
1.095
|
0.093
|
0.316
|
11.741
|
0.000
|
| Risk
factors score
|
0.326
|
0.091
|
0.141
|
3.596
|
0.000
|
| BMI
|
0.165
|
0.043
|
0.128
|
3.856
|
0.000
|
| AGE
|
-4.80E-02
|
0.013
|
-0.097
|
-3.632
|
0.000
|
| TG
|
0.281
|
0.084
|
0.103
|
3.346
|
0.001
|
| LDL
|
0.321
|
0.158
|
0.062
|
2.034
|
0.042
|
DISCUSSION
PI
is converted to insulin in the secretory granules of pancreatic b
cells. Two endoproteolytic activities are responsible for this
conversion. These activities correspond to the two endoprotease
types PC1 and PC2, two members of the mammalian family of subtilisin-like
proteases, which are related to the yeast kex2 gene products. Type 1
endoprotease (PC1) cleaves on the C-terminal side of the pair of
basic amino acids Arg31-Arg32 linking the B-chain and connecting
peptide (C-peptide) and type 2 endoprotease (PC2) on the C-terminal
side of Lys64-Arg65 linking the C-peptide and the A-chain. It has
been reported that C-terminal basic residues generated by such
cleavages are then trimmed by carboxypeptidase[22], and PI is
cleaved sequentially, first by PC1 which cleaves at the 32,33 sites
and then by PC2 which cleaves at the 64,65 sites to produce mature
insulin and C-peptide[23]. Under physiological conditions, only a
small amount of intact and split PI is co-secreted with insulin from
the pancreatic b-cells. However, in type-2
diabetes[24] and other
pathological conditions[11-13], PI and PI split products could be
markedly elevated. Thus, it is possible that hyperinsulinemia in
subjects with insulin resistance syndrome (IRS) may reflect
increased PI concentrations rather than increased levels of insulin
itself. The disagreement in results could be attributed to the
difference in laboratory methods and in the geological distribution
of investigated populations. For these reasons, we studied a
population-based sample of 1196 Chinese adults living in the Pizhou
City, Jiangsu Province of China. So far no population-based
epidemiological studies on the relationship between the clustering
of cardiovascular risk factors and TI versus PI have been reported.
The median and quartile
range of fasting TI concentration in this study was 4.91 mIu/L and
3.01-7.09 mIu/L in response to a fasting PI of 3.49 pmol/L and
2.14-5.68 pmol/L. The TI and PI concentrations reported here are
lower than those reported previously in a population-based study of
diabetes and cardiovascular diseases in Mexican Americans and
non-Hispanic whites[25], which might be attributed to the difference
in ethnicity and laboratory measurement. The statistical results of
ANCOVA after the age and sex were adjusted indicate that the
subjects with cardiovascular risk factors including hypertension,
hyperglycemia, obesity, visceral obesity, dyslipidemia and risk
factor clustering have both hyperinsulinemia and hyperproinsulinemia
rather than either hyperinsulinemia or hyperproinsulinemia alone. In
general, our results are in agreement with the previous results in
diabetic subjects[26], young nondiabetic male survivors with
myocardial infarction[27], hypertension subjects[13], and subjects
with dyslipidemia[25]. The results of univariate and multivariate
analyses reveal that the concentrations of TI and PI are closely
associated with cardiovascular risk factor clustering independent of
age, sex, BMI, WC, blood pressure, fasting blood glucose and lipid,
and the results are in accordance with the cohort epidemiological
results that cardiovascular diseases and all-cause mortality are
increased in subjects with metabolic syndrome, even in the absence
of baseline CVD and diabetes[28]. The age-adjusted prevalence of
metabolic syndrome in Americans is similar in men (24.0%) and women
(23.4%), and about 47 million US residents have metabolic syndrome
based on 2000 census data[29]. Therefore, early identification,
treatment, and prevention of metabolic syndrome presents a major
challenge to the health care professionals facing an epidemic of
overweight and sedentary lifestyle.
This study concludes that
both TI and PI are elevated in serum when the risk factors are
co-presented, which means that it is not the premature secretion of
insulin but the total activity of b
cells is promoted in this
situation. However, the mechanisms by which TI contributes to the
clustering of cardiovascular risk factors are incompletely
understood, and the defects in nonesterified fatty acid (NEFA)
metabolism which have been implicated in the abnormal lipid and
glucose metabolism, may characterize the clustering of
cardiovascular risk factors[8]. It has been shown that PI is at
least as strong as insulin and can independently increase the level
of PAI-1 activity, thereby lowering fibrinolytic activity[27]. TI
and PI are secreted together from the b
cells and probably exert
their biological effects in the body independently of each other,
but this does not exclude the possibility of coinciding effects
later in the causal path of cardiovascular risk factor clustering
(e.g., PAI-1 activity).
In conclusion, TI and PI
are closely associated with the clustering of cardiovascular risk
factors, further studies are needed to investigate quantitatively
the prognostic significance of these variables.
ACKNOWLEDGEMENTS
Special
thanks to Dr Lennart Andersen, Dr Jens Christian Wortmann, and Dr
Thomas Peter Dyrberg, at Novo Nordisk, Bagsvaerd, Denmark, for
providing the free monoclonal antibodies including OXI-005, HUI-018,
PEP-001 and HUI-001.
REFERENCES
1
Ducimetiere P, Eschwege E, Papoz L, Richard JL, Claud JR,
Rosselin G. Relationship of plasma insulin levels to the
incidence
of myocardial infarction and coronary heart disease mortality in a
middle-aged population. Diabetologia
1980; 19: 205-210
2
Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as
an independent risk factor for cardiovascular disease: A
26-year
follow-up of participants in the Framingham heart study. Circulation
1983; 65: 968-977
3
Castelli WP. Epidemiology of coronary heart disease: the
Framingham study. Am J Med 1984; 76: 4-12
4
Reaven GM. Insulin resistance/compensatory hyperinsulinemia,
essential hypertension, and cardiovascular disease.
J Clin
Endocrinol Metab 2003; 88: 2399-2403
5
Kaplan NM. The deadly quartet: upper-body obesity, glucose
intolerance, hypertriglyceridemia, and hypertension. Arch
Intern Med
1989; 149: 1514-1520
6
DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted
syndrome responsible for NIDDM, obesity, hypertension,
dyslipidemia,
and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14:
173-194
7
Liao D, Sloan RP, Cascio WE, Folsom AR, Liese AD, Evans GW,
Cai J, Sharrett AR. Multiple metabolic syndrome is
associated with
lower heart rate variability. The Atherosclerosis Risk in
Communities Study. Diabetes Care
1998; 21: 2116-2122
8
Egan BM, Greene EL, Goodfriend TL. Insulin resistance and
cardiovascular disease. Am J Hypertens
2001; 14(6 Pt 2): 116S-125S
9
Berson SA, Yalow RS. Assay of plasma insulin in human
subjects by immunological methods. Nature
1959; 184: 1648-1649
10
Sobey WJ, Beer SF, Carrington CA, Clark PM, Frank BH, Grany
IP, Luzio SD, Owens DR, Schneider AE, Siddle K.
Sensitive and
specific two-site immunoradiometric assays for human insulin,
proinsulin, 65-66 split and 32-33 split
proinsulins. Biochem J 1989;
260: 535-541
11
Oh JY, Barrett-Connor E, Wedick NM. Sex differences in the
association between proinsulin and intact insulin with
coronary
heart disease in Nondiabetic older adults. The Rancho Bernardo
Study. Circulation 2002; 105: 1311-1316
12
Lindahl B, Dinesen B, Eliasson M, Roder M, Hallmans G,
Stegmayr B. High proinsulin levels precede first-ever stroke in
a
nondiabetic population. Stroke 2000; 31: 2936-2941
13
Ferreira SR, Franco LJ, Gimeno SG, Iochida LC, Iunes M. Is
insulin or its precursor independently associated with
hypertension?
An epidemiological study in Japanese-Brazilians. Hypertension 1997;
30(Pt 2): 641-645
14
Takahiro O, Yoshio F, Shinji M, Sayaka T, Miho M, Takeshi T,
Mitsumasa O, Tadaaki I. Eicosapentaenoic acid improves
endothelial
function in hypertriglyceridemic subjects despite increased lipid
oxidizability. Am J Med Sci
2002; 324: 247-253
15
Andersen L, Dinesen B, Jørgensen
PN, Poulsen F, Roder ME. Enzyme immunoassay for intact human insulin
in serum
or plasma. Clin Chem 1993; 39: 578-582
16
Kjems LL, Roder ME, Dinesen B, Hartling SG, Jorgensen PN,
Binder C. Highly sensitive enzyme immunoassay of
proinsulin
immunoreactivity with use of two monoclonal antibodies. Clin Chem
1993; 39: 2146-2150
17
Guidelines subcommittee of the WHO-ISH Mild Hypertension
Liaison Committee. 1999 World health
organization-international
society of hypertension guidelines for the management of
hypertension.
J Hypertension 1999; 17: 151-183
18
The expert committee on the diagnosis and classification of
diabetes mellitus. Report of the expert committee on the
diagnosis
and classification of diabetes mellitus. Diabetes Care 2002;
25(Suppl 1): s5-s19
19
Expert panel on detection, evaluation, and treatment of high
blood cholesterol in adults. Executive summary of the
third report
of the national cholesterol education program(NCEP) expert panel on
detection, evaluation, and treatment
of high blood cholesterol in
adults (adult treatment panel III). JAMA 2001; 285: 2486-2497
20
Barreto SM, Passos VM, Firmo JO, Guerra HL, Vidigal PG,
Lima-Costa MF. Hypertension and clustering of cardiovascular
risk
factors in a community in Southeast Brazil-The Bambui Health and
Ageing Study. Arq Bras Cardiol
2001; 77: 576-581
21
Zhou BF, Wu YF, Zhao LC, Li L, Yang J, Li X. Relationship of
central obesity to cardiovascular risk factors and their
clustering
in middle aged Chinese population. Zhonghua Xinxue Guanbing Zazhi
2001; 29: 70-73
22
Davidson HW, Rhodes CJ, Hutton JC. Interaorgenellar Ca and pH
control proinsulin cleavage in the pancreatic B-cell via
two
site-specific endopeptidases. Nature 1988; 333: 93-96
23
Rhodes CJ, Alarcon C. What beta-cell defect could lead to
hyperproinsulinemia in NIDDM? Some clues from recent
advances made
in understanding the proinsulin processing mechanism. Diabetes 1994;
43: 511-517
24
Roder ME, Porte D Jr, Schwartz RS, Kahn SE.
Disproportionately elevated proinsulin levels reflect the degree of
impaired
B cell secretory capacity in patients with noninsulin-dependent
diabetes mellitus. J Clin Endocrinol Metab
1998; 83: 604-608
25
Haffner SM, Mykkanen L, Stern MP, Valdez RA, Heisserman JA,
Bowsher RR. Relationship of proinsulin and insulin to
cardiovascular
risk factors in nondiabetic subjects. Diabetes 1993; 42: 1297-1302
26
Goetz FC, French LR, Thomas W, Gingerich RL, Clements JP. Are
specific serum insulin levels low in impaired glucose
tolerance and
type 2 diabetes? Measurement with a radioimmunoassay
blind to proinsulin, in the population of Wadena,
Minnesota.
Metabolism 1995; 44: 1371-1376
27
Bavenholm P, Proudler A, Tornvall P, Godsland I, Landou C, de
Faire U, Hamsten A. Insulin, intact and split proinsulin,
and
coronary artery disease in young men. Circulation 1995; 92:
1422-1429
28
Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E,
Tuomilehto J, Salonen JT. The metabolic syndrome
and total and
cardiovascular disease mortality in middle-aged men. JAMA 2002; 288:
2709-2716
29
Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic
syndrome among US adults: Finding from the third National
Health and
Nutrition Examination Survey. JAMA 2002; 287: 356-359
Edited
by
Wang XL and Ren SY Proofread
by Zhu LH
| |